What's new

Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 26, Status: Authorised

Mar 5, 2025 - 14:27
 0
Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 26, Status: Authorised
Human medicines European public assessment report (EPAR): Skyrizi, risankizumab, Date of authorisation: 26/04/2019, Revision: 26, Status: Authorised
Read More

Tags:

Previous Article

Jazz hands over $935M to buy Chimerix for near-approval cancer drug

Next Article

Mondelez promotes Norberto Chaclin to chief R&D officer

Related Posts

Orphan designation: amitriptyline Treatment of erythromelalgia, 21/06/2022 Withdrawn

Orphan designation: amitriptyline Treatment of erythrom...

Feb 20, 2025  0

Herbal medicinal product: Centaurii herbaArray, F: Assessment finalised

Herbal medicinal product: Centaurii herbaArray, F: Asse...

Feb 14, 2025  0

EMEA-003301-PIP01-22-M01

EMEA-003301-PIP01-22-M01

Feb 17, 2025  0